Leen Ann M.
Known title: Chief Scientific OfficerCIK: 0001763026
Associated companies
Transaction History
| KLRS | ▲ Buy | Grant | 43,750 | $0 | 2/2/2023 | View on chart |
| KLRS | ▲ Buy | Grant | 15,000 | $0 | 8/16/2022 | View on chart |
| KLRS | ▲ Buy | Grant | 14,000 | $0 | 7/1/2022 | View on chart |
| KLRS | ▲ Buy | Grant | 23,256 | $0 | 1/18/2022 | View on chart |
| KLRS | ▼ Sell | Open Market | 100 | $2K | 11/16/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 6,122 | $134K | 11/15/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 500 | $12K | 11/12/2021 | View on chart |
| KLRS | ▼ Sell | Open Market | 14,266 | $318K | 11/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI
Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI. Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.